RxDoctor Payments Data

James Rapley, MD

Psychiatry · Norfolk, VANPI 1235399973

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $81,875 of the $98,250 with a category attached, or 83.3%. AbbVie accounts for 97.9% of it on its own, with 14 other manufacturers making up the rest. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$98,250in general payments, 2019–2025

Across 266 payments — averaging $369.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$96K
  • Otsuka America Pharmaceutical, Inc.$526
  • Eko Health, Inc.$399
  • Johnson & Johnson$240
  • E.r. Squibb & Sons, L.L.C.$187
  • Teva Pharmaceuticals USA, Inc.$176
  • plus $555 from 9 others

What the payments were for

  • Consulting fees$1,4501%
  • Speaking & faculty fees$81,87583%
  • Travel & lodging$8,2878%
  • Food & beverage$6,1026%
  • Education$1370%
  • Other$3990%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,250 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$41,084
Medicare patients
79
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole16$24,884
VraylarCariprazine Hcl13$19,177
Aripiprazole15$1,348
Fluoxetine Hcl14$1,236
Duloxetine Hcl49$1,197
Venlafaxine Hcl ErVenlafaxine Hcl19$938
Mirtazapine51$749
Quetiapine Fumarate20$283
Gabapentin21$267
Methylphenidate Hcl11$233
Trazodone Hcl20$201
Lamotrigine19$189
Hydroxyzine Hcl18$111
Sertraline Hcl14$111
Lorazepam19$19

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$526$24,88416 claims
AbbVieVraylar$96,167$19,17713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →